🇺🇸 FDA
Company

CORCEPT

CORCEPT THERAPEUTICS INC

CORT pharma USA

Quick answer

CORCEPT is a pharma company (CORT) headquartered in REDWOOD CITY, CA, USA with 24 tracked pipeline programs.

Pipeline (24)

project

Mifepristone

Depressive Disorder, Major

Phase 3 · small_molecule · completed

1 trials project

Nab-paclitaxel 80 mg/m^2

Ovarian Neoplasm

Phase 3 · small_molecule · active

1 trials project

Relacorilant

Hypercortisolism

Phase 3 · small_molecule · completed

1 trials project

Relacorilant, 100 mg and 25 mg

Metastatic Pancreatic Ductal Adenocarcinoma

Phase 3 · small_molecule · terminated

1 trials project

mifepristone

Psychotic Depression

Phase 3 · small_molecule · terminated

1 trials project

mifepristone

Cushing's Syndrome

Phase 3 · small_molecule · completed

2 trials project

mifepristone

Major Depressive Disorder

Phase 3 · small_molecule · completed

5 trials project

mifepristone

Cushing's Disease

Phase 3 · small_molecule · terminated

2 trials project

relacorilant

Cushing Syndrome

Phase 3 · small_molecule · active

2 trials project

CORT125134

Cushing's Syndrome

Phase 2 · small_molecule · completed

1 trials project

Dazucorilant 300 mg

Amyotrophic Lateral Sclerosis

Phase 2 · small_molecule · active

1 trials project

Enzalutamide

Metastatic Breast Cancer

Phase 2 · small_molecule · active

1 trials project

Exicorilant

Metastatic Castration-Resistant Prostate Cancer

Phase 2 · small_molecule · terminated

1 trials project

Mifepristone

Weight-Gain Prevention

Phase 2 · small_molecule · completed

1 trials project

Mifepristone

Alzheimer's Disease

Phase 2 · small_molecule · terminated

1 trials project

Mifepristone

Non-Small Cell Lung Cancer (NSCLC)

Phase 2 · small_molecule · terminated

1 trials project

Mifepristone

Central Adrenal Insufficiency

Phase 2 · small_molecule · terminated

1 trials project

Mifepristone 1200 mg daily

Treatment-resistant PTSD

Phase 2 · small_molecule · active

1 trials project

Miricorilant

Antipsychotic-induced Weight Gain (AIWG)

Phase 2 · small_molecule · completed

1 trials project

Miricorilant

Nonalcoholic Steatohepatitis (NASH)

Phase 2 · small_molecule · active

3 trials project

Miricorilant (Cohort A)

Nonalcoholic Steatohepatitis (NASH)

Phase 2 · small_molecule · active

1 trials project

Miricorlilant

Antipsychotic-induced Weight Gain (AIWG)

Phase 2 · small_molecule · completed

1 trials project

Nenocorilant 200 mg

Neoplasms

Phase 2 · small_molecule · active

1 trials project

Relacorilant

Recurrent Ovarian Cancer

Phase 2 · small_molecule · completed

1 trials

Drugs (1)

drug

relacorilant

LIFYORLI (COPACKAGED)

Patents (8)

patent

US 12370175

Glucocorticoid receptor modulators to treat pancreatic cancer

Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12370188

Formulations of dazucorilant, a glucocorticoid receptor modulator

Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12336985

Methods for shrinking pituitary tumors

Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12290551

Methods for imaging and treatment of somatostatin-receptor positive tumors

Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12285425

Glucocorticoid receptor modulators to treat cervical cancer

Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12263169

Methods of treating neuroepithelial tumors using selective glucocorticoid recept

Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12226417

Fatty liver disease treatment using glucocorticoid and mineralocorticoid recepto

Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12226412

Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)